CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 344 enrolled
Drug / intervention
LY3154207 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03305809
NCT03305809Phase 2Completed
CompareCT.gov

Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

Eli Lilly and Company·interventional·Posted Oct 10, 2017·Updated Jul 23, 2021

In Brief

A Phase 2 clinical trial evaluating LY3154207 and Placebo for Lewy Body Dementia. Completed, enrolled 344 participants across 77 sites in 3 countries.

Detailed Summary

A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLewy Body Dementia
CountriesCanada, Puerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 10, 2017
Enrollment StartNov 9, 2017
Primary CompletionJul 10, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.7 years ago

Interventions

LY3154207drug

Administered orally.

Placebodrug

Administered orally.